ClinicalTrials.gg
Active, not recruitingNCT06851806SynagisUpdated Sep 9, 2026

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

An interventional study of Palivizumab 15 mg/kg in Respiratory Syncytial Virus (RSV), sponsored by AstraZeneca. Active, not recruiting at 9 sites in India. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by AstraZeneca · Not applicable, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Sex
All
01

Study summary

This is a Phase IV, prospective, open-label, multicentre study to evaluate the safety of palivizumab IM injection for the prevention of severe LRTD in Indian infants and children who are at high-risk of RSV disease. All enrolled participants will receive palivizumab 15 mg/kg IM injection once a month for up to 5 injections during the study. Children who undergo cardiac surgery with cardiopulmonary bypass during the study should receive an additional dose of study intervention immediately after surgery, when medically stable for IM injection as determined by the physician. Prior to each study intervention administration, all participants will undergo safety assessments. A follow-up visit will be performed telephonically with the parent(s) or legal guardian(s) of all participants 30 days after their last injection of palivizumab.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)

Keywords

  • Phase IV
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants at risk of severe RSV disease defined as fulfilling at least one of the following:

    1. Infants born ≤ 35 wGA and are \< 6 months of age at enrolment.
    2. Children \< 24 months of age at enrolment and requiring treatment for BPD within the last 6 months.
    3. Children \< 24 months of age and with haemodynamically significant CHD.
  2. Written obtained from the participant's parent(s)/legal guardian and the participant's parent(s)/legal guardian is able to understand and comply with the requirements of the protocol including follow-up visits as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Hospitalisation at the time of enrolment, unless the discharge is expected within 30 days of the time of enrolment
  2. Required mechanical ventilation (including continuous positive airway pressure) or other mechanical respiratory or cardiac support at the time of enrolment.
  3. Anticipated cardiac surgery within 2 weeks after enrolment.
  4. Anticipated survival of \< 6 months after enrolment in the trial.
  5. Active LRTD, including RSV infection at the time of enrolment and/or study intervention administration.
  6. Any fever (≥ 38.0°C) or acute illness within 7 days prior to product administration.
  7. Known history of evolving or unstable neurologic disorder.
  8. Known history of unstable cardiac or respiratory status, including cardiac defects so severe that survival is not expected or for which cardiac transplantation is planned or anticipated.
  9. Known allergy, including to immunoglobulin products, or history of allergic reaction.
  10. Receipt of palivizumab or other RSV monoclonal antibodies or any RSV vaccine, including maternal RSV vaccination.
  11. Receipt of any monoclonal or polyclonal antibody (for example, immune globulin, intravenous immunoglobulin) or anticipated use during the study.
  12. Concurrent enrolment in another interventional study.
  13. Children of employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
  14. Judgment by the investigator that the participant should not participate in the study if the participant or the participant's parent/legal guardian is unlikely to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Study Arm

    All the eligible participants will receive palivizumab 15 mg/kg on Days 1, 31, 61, 91, and 121.

    Drug: Palivizumab 15 mg/kg

Interventions

  • DrugPalivizumab 15 mg/kg

    Drug page: Palivizumab

    Single-dose liquid solution vials, 50 mg/0.5 mL, IM injection

06

What researchers measure

Primary outcomes

  1. To assess the safety of palivizumab prophylaxis when administered to preterm infants (≤ 35 wGA), children with BPD (< 24 months) and/or children with haemodynamically significant CHD (< 24 months).

    1\) To determine percentage of participants with AEs and SAEs. 2) To assess nature, incidence, and severity of all AEs including unexpected adverse drug reactions 2)To determine percentage of participants with AEs that lead to study intervention discontinuation.

    Time frame: screening to day 151

07

Study locations

9 sites
  • Research Site
    Hyderabad, 500084, India
  • Research Site
    Jhānsi, 284128, India
  • Research Site
    Kanpur, 208011, India
  • Research Site
    Kolkata, 700073, India
  • Research Site
    Mysore, 570001, India
  • Research Site
    Nagpur, 440012, India
  • Research Site
    Nagpur, 441108, India
  • Research Site
    Pune, 411006, India
  • Research Site
    Vidyanagar, Hubballi, 580022, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Feb 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 28, 2025
StartActual
Dec 10, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06851806
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Dec 10, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palivizumab

Start the discussion